HAVEN 1 and HAVEN 3 were randomised clinical trials, HAVEN 2 and HAVEN 4 were non-randomised clinical trials. Randomised study designs are listed before non-randomised study designs.
HEMLIBRA was evaluated in HAVEN – an extensive clinical trial programme in patients with congenital haemophilia A1–5
- All HAVEN studies met their bleed rate endpoints2-5
HAVEN 3 evaluated HEMLIBRA prophylaxis in severe congenital haemophilia A (N=152)2
- Randomised, multicentre, open-label, phase III study, in adult and adolescent males2
- HEMLIBRA every week (QW) and every two weeks (Q2W) were compared with episodic FVIII; an intra-individual comparison also evaluated HEMLIBRA QW vs. prior FVIII prophylaxis2
- HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW or 3.0 mg/kg/Q2W thereafter2
Related links:
-
HAVEN 3 study design details
Males with severe congenital haemophilia A (endogenous FVIII activity, <1%) without inhibitors, ≥12 years; treated with episodic FVIII or FVIII prophylaxis* in the prior 24 weeks (N=152).2,6
*At least five bleeding events in the prior 24 weeks required for episodic FVIII. No bleed requirements with prior prophylaxis.6
Patients in Arm C received no prophylaxis; after completing ≥24 weeks in the trial they could receive HEMLIBRA prophylaxis Q2W (and remain in Arm C). For all participants, additional FVIII was administered at investigator-determined doses for breakthrough bleeding.
Primary efficacy endpoint: treated bleeds at ≥24 weeks in Arm A vs. C and Arm B vs. C.2
Two patients (one in Arm A and one in Arm C) were lost to follow-up and not treated. These patients were included in the primary efficacy analysis, but not in the surgery analysis.2,7
The non-interventional study (NIS) followed patients receiving FVIII prophylaxis (n=48) and prospectively collected data on bleeds and FVIII administration. The availability of granular data enabled paired analyses, using identical definitions and methodologies to HAVEN 3. Each patient received adequate prophylaxis, as determined by investigators. The NIS resulted in an intra-individual comparison analysis – part of HAVEN 3, Arm D, which was controlled for inter-individual variability (e.g. bleeding characteristics, risk factors for bleeds and patient recognition of bleeds).2,8
Data cut-off: 15 September 2017.
For full study details please refer to the
HAVEN 3 publication
-
HAVEN 3 participant demographic and clinical characteristics
*All values based on electronic case-report forms. Does not include data from the non-interventional study.6
†In Arm B, one patient reported ‘Other’ as the product used. Therefore, percentages based on 34 participants in Arm B and 151 participants in the Total column.6
HAVEN 1 evaluated HEMLIBRA prophylaxis in congenital haemophilia A with FVIII inhibitors (N=109)3
- Randomised, multicentre, open-label, phase III study, in adult and adolescent males3
- HEMLIBRA QW was compared with episodic bypassing agents (BPAs); an intra-individual comparison
also evaluated HEMLIBRA QW vs. prior BPA prophylaxis3 - HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW thereafter3
-
HAVEN 1 study design details
Males with congenital haemophilia A with FVIII inhibitors, ≥12 years, ≥40 kg; treated with episodic BPAs or BPA prophylaxis in the prior 24 weeks (N=109).3,9
Primary efficacy endpoint: treated bleeds at ≥24 weeks in Arm A vs. B.
Patients in Arm B received no prophylaxis and no subcutaneous control injections; after completing ≥24 weeks in the trial they could receive HEMLIBRA prophylaxis QW (and remain in Arm B). All participants receiving HEMLIBRA could receive episodic treatment with BPAs for breakthrough bleeding, as needed.
One patient in Arm A discontinued prior to treatment; this patient was included in the primary efficacy analysis and the surgical analysis. Since the data cut-off for the primary analysis, an additional four patients were enrolled and included in the surgery analysis.7,9
Arm C included patients from the intra-individual comparison from the non-interventional study (NIS, n=24). This prospective NIS evaluated real-world bleeding and safety data. Eligible patients were subsequently able to participate in HAVEN 1. Arm D included NIS participants enrolled after randomisation deadline and included in the safety analysis (n=7 at cut-off).3 Data from Arms C and D are not presented here; for details, please refer to the HAVEN 1 publication
Data cut-off: 25 October 2016.
For full study details please refer to the
HAVEN 1 publication
-
HAVEN 1 participant demographic and clinical characteristics
*All values based on electronic case-report forms and not on data from the NIS.3
†All participants had a FVIII inhibitor titre of ≥5.0 Bethesda units/ml.3
HAVEN 2 evaluated HEMLIBRA prophylaxis in congenital haemophilia A with FVIII inhibitors (N=88)4
- Non-randomised, multicentre, open-label, phase III study, in paediatric males4
- HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW, 3.0 mg/kg/Q2W or 6.0 mg/kg/Q4W thereafter4
-
HAVEN 2 study design details
Males with congenital haemophilia A with FVIII inhibitors, <12 years*; treated with episodic BPAs or BPA prophylaxis in the prior 24 weeks (N=88).4
*Participants aged <2 years were enrolled after results of the interim analysis if they had a high medical need (n=8). Participants aged 12–17 years and <40 kg were included in Arm A, but not in the efficacy analysis (n=3).4
HAVEN 2 was designed as a descriptive study with no defined primary or secondary endpoints. Efficacy endpoints included the rate of treated bleeding events.4
The Q2W and Q4W cohorts (Arms B and C) were added later for characterisation of PK, to support extrapolation. No patients <2 years old or 12–17 years old could enrol in these cohorts.4
Data cut-off: 30 April 2018.
For full study details please refer to the
HAVEN 2 publication
HAVEN 4 evaluated HEMLIBRA prophylaxis in congenital haemophilia A, classified as severe or with FVIII inhibitors (N=48)5
- Non-randomised, multicentre, open-label, phase III study, in adult and adolescent males5
- HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks, followed by 6.0 mg/kg/Q4W thereafter5
-
HAVEN 4 study design details
Males with congenital haemophilia A, classified as severe or with FVIII inhibitors, ≥12 years; treated with BPAs or FVIII in the prior 24 weeks (N=48).5
Patients in the initial run-in cohort (n=7) received HEMLIBRA 6.0 mg/kg/Q4W for ≥24 weeks to assess safety and establish pharmacokinetics of the regimen.
Patients in the expansion cohort (n=41) were included in the efficacy analysis: treated annualised bleed rate (ABR). At the time of analysis all patients had received ≥24 weeks treatment.
Data cut-off: 15 December 2017.
For full study details please refer to the
HAVEN 4 publication
-
HAVEN 4 participant demographic and clinical characteristics
*Includes one patient with mild haemophilia, inhibitors (32 Bethesda units/ml) and <1% FVIII activity at study entry.5
BPA, bypassing agent; FVIII, Factor VIII; PK, pharmacokinetics; QW, every week; Q2W, every 2 weeks; Q4W, every 4 weeks.
References:
- HEMLIBRA Summary of Product Characteristics.
- Mahlangu J et al. N Eng J Med 2018;379:811–22.
- Oldenburg J et al. N Eng J Med 2017;377:809-18.
- Young G et al. Blood 2019 [Epub ahead of print].
- Pipe S et al. Lancet Haematol 2019;6(6):e295–e305.
- Mahlangu J et al. N Eng J Med 2018;379:811–22 [Supplementary Appendix].
- Santagostino E et al. ISTH 2019 [Oral Presentation].
- Mahlangu J et al. WFH 2018;854 [Oral Presentation].
- Oldenburg J et al. N Eng J Med 2017;377:809-18 [Supplementary Appendix].
- Pipe S et al. WFH 2018 [Oral Presentation].
M-GB-00001037
Date of preparation: August 2020